Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models

PURPOSE: Preclinical characterization of cetrelimab (JNJ-63723283), a fully humanized immunoglobulin G4 kappa monoclonal antibody targeting programmed cell death protein-1 (PD-1), in human cancer models. METHODS: Cetrelimab was generated by phage panning against human and cynomolgus monkey (cyno) PD...

Descripción completa

Detalles Bibliográficos
Autores principales: DeAngelis, Nikki, Ferrante, Catherine, Powers, Gordon, Sendecki, Jocelyn, Mattson, Bethany, Pizutti, Darlene, Packman, Kathryn, Wang, Weirong, Trouba, Kevin, Nanjunda, Rupesh, Wheeler, John, Brittingham, Ray, Wu, Sheng-Jiun, Luo, Jinquan, Lorenzi, Matthew V., Verona, Raluca I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956561/
https://www.ncbi.nlm.nih.gov/pubmed/35298699
http://dx.doi.org/10.1007/s00280-022-04415-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956561/
https://www.ncbi.nlm.nih.gov/pubmed/35298699
http://dx.doi.org/10.1007/s00280-022-04415-5

Ejemplares similares